<DOC>
	<DOCNO>NCT02244255</DOCNO>
	<brief_summary>1 . To study early onset symptomatic relief afford FLOMAX® capsule , 0.4 mg daily compare HYTRIN® capsule , 5 mg ( titration ) daily patient sign symptom benign prostatic hyperplasia ( BPH ) 2 . To evaluate patient 's tolerability use FLOMAX® capsule 0.4 mg daily comparison HYTRIN® capsule , 5 mg ( titration ) daily treatment symptom benign prostatic hyperplasia</brief_summary>
	<brief_title>FLOMAX® Versus HYTRIN® Patients With Signs Symptoms Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Terazosin</mesh_term>
	<criteria>Male patient ( 45 year age old ) diagnose benign prostatic hyperplasia Patients total score AUA Symptom Index BPH least 13 point three initial visit ( Visits 1 , 2 3 ) A baseline prostate specific antigen ( PSA ) ≤ 4.0 ng/ml Patients able give write informed consent perform screen examination test Patients judge investigator reliable able follow protocol procedure ( include return visit schedule ) , cooperate completion test relate safety efficacy Patients history allergy alpha blocker , alpha/beta blocker patient `` first dose hypotensive episode '' upon start therapy alpha blocker Patients currently treat , last 3 month , treat finasteride Participated investigational drug study within 4 week prior start placebo phase Patients take medication follow class unable discontinue least two week study duration study Alpha adrenergic block agent Alpha adrenergic agonist Drugs anticholinergic activity ( include antihistamine ) Antispasmodics Parasympathomimetics cholinomimetics Peripheral central neurologic disease include , limited , transient ischemic attack , stroke , dementia , multiple sclerosis , spinal cord injury , recurrent episode dizziness , vertigo , loss consciousness , clinically evident diabetic neuropathy , brain and/or spinal cord tumor History pathological fall ( unintentional change body position ) occur circumstance normal homeostatic mechanism would ordinarily maintain stability , syncope last year More one episode angina within past 6 month Ambulation require assistance ( i.e. , cane , walker , etc . ) Documented myocardial infarction ( ECG ) within past 6 month evidence myocardial infarction ECG whose age determine New York Heart Association Class III IV congestive heart failure Prosthetic heart valve , cardiac device prior history endocarditis Clinically significant cardiac arrhythmia either diagnose ECG record medical history , whether accompany symptom ( e.g. , dizziness , presyncope , syncope , unsteadiness ) Infravesical obstruction history due : Vesical neck contracture Clinical suspicion prostate carcinoma Mullerian duct cysts Urethral obstruction due stricture , valve , sclerosis urethral tumor Inflammatory infectious condition Detrusorsphincter dyssynergia Prior transurethral resection prostate ( TURP ) open prostatectomy History instrumentation urinary tract ( cytoscopy catheterization ) within 30 day prior start study Prior pelvic surgery malignancy bowel resection History diagnosis genitourinary malignancy History episode acute urinary retention within three month prior start study . ( Urinary retention consider acute patient send hospital catheterization ) Patients current diagnosis either bladder , ureter , kidney stone Patients current diagnosis suspect prostatitis Patients history neurogenic bladder Urinary tract infection ( i.e. , positive urine culture ) yield pathogenic bacteria &gt; 10**5 colony form unit ( CFU ) per milliliter properly obtain clean void urine specimen properly culture laboratory report urinary tract infection signs/symptoms indicative urinary tract infection [ increase WBC 's urine ( 1530 white blood cell ( WBC ) /high powered field ) , dysuria , costovertebral tenderness , urinary frequency accompany fever ] within four week baseline ( Visit 3 ) Evidence significant renal dysfunction base upon serum creatinine great two time upper limit normal level establish central laboratory use study Laboratory test screen phase : Hemoglobin : &lt; 12.0 g/dL Leukocytes : &lt; 3000/mm3 Liver Enzymes : ( serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamate pyruvate transaminase ( SGPT ) , alkaline phosphatase ) : two time upper limit normal level establish central laboratory use study Clinically relevant condition might interfere patient 's ability participate study include , limited , follow : neurologic , gastrointestinal , cardiovascular include uncontrolled hypertension define sit diastolic blood pressure ≥ 95 mmHg without treatment , hepatic , renal , psychiatric , hematologic respiratory disease , clinically relevant laboratory abnormality base upon investigator 's judgment Hypertensive patient initially use HYTRIN® monotherapy hypertension BPH Patients cancer diagnosis cancer within five year baseline Patients receive cimetidine , warfarin , herbal medication specifically treatment urological problem within four week prior baseline Patients show poor compliance initial placebo period : returning unused medication bottle Visits 2 3 take &lt; 80 % &gt; 120 % prescribed dose visit interval Visit ( 1 , 2 3 ) Postural symptom initial placebo period , e.g. , lightheadedness ( three occasion ) , faint , blur loss vision , profound weakness , unsteadiness , without change blood pressure and/or pulse rate Patients poorly control diabetes mellitus ( urine positive glucose ( &gt; 1+ ) 2 urinalysis placebo evaluation period )</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>